HYDERABAD: Hyderabad-based Zenara Pharma has announced the launch of oral drugs Nirmatrelvir and Ritonavir tablets in a combi-pack as treatment option for mild to moderate Covid-19 cases.
The pharma company had received approval from the Central Drugs Standard Control Organization (CDSCO) last month to manufacture and market the product. The tablet, which will be sold under the brand name ‘Paxzen’, is being manufactured at Zenara’s facility in Hyderabad.
The product was given approval by the US FDA in Devember 2021, becoming the first oral pill to be approved by them.
According to a press release, the product can be administered at home and that it indicated the risk of death and hospitalization has reduced by 89% when taken in timely manner against Covid-19.
One box of medicines, equivalent to one full course of treatment, containing 20 tablets of Nirmatrelvir 150mg and 10 tablets of Ritonavir 100 mg will be available at a price of Rs. 5,200.
Co-founder and Managing Director, Zenara Pharma, Dr. Jagadeesh Babu Rangisetty said, “We have launched this product in India with an aim to bring the best treatment options against Covid within reach of patients in our country. Our product, Paxzen, has been proven equivalent to Paxlovid through a Bio Equivalence study, based on which we have received the approval from the regulatory authorities.”
Zenara has informed that patients or hospitals may contact this dedicated help line number – 72079 28889 or visit their website www.zenarapharma.com for availability details of Paxzen in their vicinity.
